Methods: Patients in a randomized phase III study conducted in western patients Optimal treatment for elderly patients with NSCLC has been under active investigation. This study evaluated the safety and initial efficacy of a novel combination regimen of oral fluoropyrimidine TS-1 plus gemcitabine (GEM) for elderly patients (pts) with advanced NSCLC. Methods: A phase I/II trial in 11 centers examined TS-1 and GEM in pts with age ≥ 70, stage IIIB/IV previously untreated NSCLC. The starting dose was 60 mg/day (day 1-14) for TS-1 and 800 mg/m 2 for GEM (day 8, 15). GEM was increased to 1000 mg/m 2 at dose level 2 and TS-1 was increased to 80 mg/day at dose level 3. Phase II portion of the study assessed the efficacy and tolerability of the combination regimen at the dose determined in the phase I portion. The primary endpoint was objective response rate. Results: Twenty two pts were enrolled in the phase I portion: 6 pts on dose level 1, 10 on dose level 2 and 6 on dose level 3. Median age of this group was 75 yrs (range 70-85). Dose limiting toxicities included Gr. 4 neutropenia (2 pts) and Gr.3 skin toxicity (4 pts). The recommended dose (RD) was TS-1 60 mg/day and GEM 1000 mg/m 2 , with which 20 pts were subsequently treated in the phase II portion. The median age of 30 pts treated with the RD was 76 yrs (range 70-85). Grade (Gr) 3/4 toxicities include neutropenia (12 pts; 7 with Gr 4), thrombocytopenia (4 pts; 0 with Gr 4), skin toxicity (8 pts), thrombus (1 pt) and peumonitis (2 pts). Nine patients (30%, 95% confidence interval [CI] = 14 to 46%) had partial responses and 16 (53%, 95% CI = 35 to 71%) had stable disease. Conclusion: Encouraging antitumor activity and safety of TS-1 plus gemcitabine support further development of this combination therapy for elderly patients with advanced NSCLC.
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The median survival time for all patients was 7.4 months with a 1-year survival of 28%. Median survival for arm A was 9.4 months, for arm B 6.8 months. (p=0.6 log rank test). Conclusions: the regimen with Carboplatin on day 8 is associated with less grade 3-4 neutropenia and thrombocytopenia without loss of response rate and is to be preferred. Organisation classification of lung tumors in 1999, a result of previous or retrospective studies based on the old classification seems unexploitable. So the GFPC started a prospective study, to establish the efficiency of Cisplatinum /Etoposide chemotherapy patients with LCNE lung cancer, diagnosed on the basis of the morphological Travis's criteria and immunohistochemistry. A total of 50 patients was planned. Methods: Patients with stage IV and stage III B (with neoplasic pleural effusion) were selected; treatment is three cycles of Cisplatinum 80mg/ m 2 d1 / Etoposide 100mg/m 2 d1d2d3 and two more cycles in case of Objective Response or Stable disease. The primary objective was the efficiency of this chemotherapy, in term of objective response and survival rate. The secondary objectives were the improvement of the pathologic diagnosis, with validation of the paranuclear granular expression of a large spectrum cytokeratin (antibodies). Results: In this protocol, 27 patients were included since May 2004. The slides of 21 cases were reviewed by a panel of pathologists, members of GFPC. Diagnoses were controlled on the basis of the Travis's criteria. 14 cases were confirmed as LCNEC. 4 were excluded on the basis of the nuclear criteria or cell size, which made them classified as small-cell carcinomas (SCC). One was excluded, because immunohistochemistry was not available. Two other patients were excluded because of the misinterpretation of the pathologic report by the clinicians. One had been concluded as a SCC, the other as a large cell carcinoma. After treatment, thirteen patients are assessable for response, a patient died eight days after inclusion in the protocol: the chemotherapy was well tolerated in eleven cases, the main toxicity was haematological, but gastric and renal toxicity appeared in two cases after the first cycles of chemotherapy and this patients had to used the other treatment . In the other cases, after 3 cycles of chemotherapy there was no Complete Response, six Partial Response, three Stable Disease and four Progressions and after 5 cycles only four Partial Response, two Stable Disease and six Progressions. At mars 2007, three patients are alive and eleven patients died. The median survival time was 33 weeks. Conclusion: With twenty seven patients included in this protocol since three years and only fourteen patients with LCNEC, it appears that this cancer is rarely diagnosed. The main pathological confusion is between small-cell and large cell-carcinoma. At last, this chemotherapy seems to give good results after three first cycles but the effectiveness with five cycles does not seem better than other combinations containing platinum. Perhaps is it necessary to propose after three cycles of induction with cisplatine -etoposide an early modification of chemotherapy in this rare shape of bronchopulmonary cancer ? Results will be updated at the meeting
